01—Abstract
Summary
Summary of the 10-Q filed May 1, 2025. Cited figures are marked; the original filing is the authoritative source.
Eli Lilly and Company (LLY) reported a strong first quarter for 2025, with revenue soaring by 45% year-over-year to $12.7 billiona, driven by significant growth in key products like Mounjaro and Zepbound.
Net income also saw a substantial increase of 23%, reaching $2.76 billionb. This impressive performance reflects robust demand and improved gross margins, although offset by higher acquired in-process R&D charges and increased marketing expenses. The company's strategic focus on innovation and pipeline development continues, as evidenced by a significant increase in acquired in-process R&D, primarily related to the Scorpion Therapeutics acquisition.
While R&D expenses saw a moderate increase, the company's commitment to developing new medicines remains a core driver of its long-term strategy. Lilly's financial position remains solid, with ample liquidity and cash flow to support its operations, ongoing investments in manufacturing capacity, and shareholder returns through its share repurchase program and dividends.
02—Key points
Key Highlights
- Revenue surged by 45% to $12.7 billion, driven by strong performance of Mounjaro and Zepbound, with U.S. revenue up 49% and international revenue up 38%.
- Net income increased by 23% to $2.76 billion, and diluted EPS grew to $3.06.
- Acquired in-process R&D (IPR&D) expenses significantly increased to $1.57 billion, primarily due to the acquisition of Scorpion Therapeutics' PI3Kα inhibitor program.
- Gross margin improved to 82.5% of revenue, benefiting from improved cost of production and a favorable product mix.
- Marketing, selling, and administrative expenses rose by 26%, reflecting investments in promotional efforts for ongoing and future product launches.
- The company repurchased $1.2 billion of shares under its $15.0 billion share repurchase program authorized in December 2024.
- Cash and cash equivalents decreased slightly to $3.09 billion, but overall financial condition remains strong with significant investments and credit facilities.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed May 1, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $12.73B$8.77B | +45.2% |
| Cost of Revenue | $2.23B$1.67B | +33.0% |
| Gross Profit | $10.50B$7.09B | +48.1% |
| SG&A Expenses | $2.47B$1.95B | +26.4% |
| Net Income | $2.76B$2.24B | +23.0% |
| EPS (Basic) | $3.07$2.49 | +23.3% |
| EPS (Diluted) | $3.06$2.48 | +23.4% |
| Shares Outstanding (Basic) | 898.70M900.80M | −0.2% |
| Shares Outstanding (Diluted) | 900.60M903.80M | −0.4% |
05—Questions
Frequently Asked Questions
What were the primary drivers of the significant revenue growth in Q1 2025?
The substantial revenue growth of 45% to $12.7 billion was primarily driven by increased volume, particularly from key products Mounjaro and Zepbound, which saw significant demand in both U.S. and international markets. A one-time benefit of $370.0 million related to an amendment of the Boehringer Ingelheim collaboration for the Jardiance product family also contributed to the increase in international revenue.
Why did acquired in-process R&D expenses increase so dramatically?
Acquired in-process R&D (IPR&D) expenses increased significantly to $1.57 billion from $110.5 million in the prior year quarter. This increase was primarily attributed to the acquisition of Scorpion Therapeutics, Inc.'s PI3Kα inhibitor program, STX-478, which is currently in Phase 1/2 clinical trials.
How is the company managing its manufacturing capacity to meet demand, especially for incretin medicines?
Eli Lilly is investing in global facilities to expand manufacturing capacity for both existing and future products, recognizing that demand for certain medicines, particularly incretin medicines like tirzepatide, has at times exceeded production. While supply considerations continue to influence market launches, production increases and delivery presentation initiatives are ongoing, with additional capacity expected over the next several years. The company is also actively addressing the issue of counterfeit, misbranded, and compounded incretins.
What is the company's outlook regarding the Inflation Reduction Act (IRA) and its impact?
The company acknowledges the ongoing impact of the Inflation Reduction Act (IRA), which requires the U.S. Department of Health and Human Services (HHS) to set prices for certain Medicare-reimbursed drugs. Jardiance was among the first ten selected products, with price setting effective in 2026. Lilly anticipates that additional significant products will be selected in the future, and the IRA is expected to meaningfully influence business strategies and could significantly impact financial results.
06—Continue